CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0100526: Neoplasm of the lungHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (15)


Name (Synonyms) Correlation
drug2508 SBRT Wiki 0.45
drug869 Device used to record voice for screening Wiki 0.45
drug203 Anatomic Pulmonary Resection Wiki 0.45
drug3176 anti-CD40 antibody Wiki 0.45
drug1379 IgG test Wiki 0.45
drug949 EHR-based Clinician Jumpstart Wiki 0.45
drug2742 Stereotactic Radiotherapy Wiki 0.45
drug1074 FLT3 Ligand Wiki 0.45
drug757 Convalescent Plasma Transfusion Wiki 0.32
drug2360 Radiation therapy Wiki 0.32
drug1433 Interferon Beta-1A Wiki 0.22
drug812 DAS181 Wiki 0.18
drug1489 Ivermectin Wiki 0.10
drug1284 Hydroxychloroquine Wiki 0.09
drug2122 Placebo Wiki 0.02

Correlated MeSH Terms (19)


Name (Synonyms) Correlation
D008175 Lung Neoplasms NIH 1.00
D002289 Carcinoma, Non-Small-Cell Lung NIH 0.32
D016491 Peripheral Vascular Diseases NIH 0.32
D058729 Peripheral Arterial Disease NIH 0.26
D014652 Vascular Diseases NIH 0.26
D009362 Neoplasm Metastasis NIH 0.22
D008103 Liver Cirrhosis, NIH 0.22
D051437 Renal Insufficiency, NIH 0.20
D009369 Neoplasms, NIH 0.19
D007676 Kidney Failure, Chronic NIH 0.17
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.16
D006333 Heart Failure NIH 0.15
D017563 Lung Diseases, Interstitial NIH 0.13
D002908 Chronic Disease NIH 0.13
D008171 Lung Diseases, NIH 0.11
D003141 Communicable Diseases NIH 0.04
D007239 Infection NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (9)


Name (Synonyms) Correlation
HP:0030358 Non-small cell lung carcinoma HPO 0.32
HP:0001395 Hepatic fibrosis HPO 0.22
HP:0004950 Peripheral arterial stenosis HPO 0.20
HP:0000083 Renal insufficiency HPO 0.20
HP:0002664 Neoplasm HPO 0.19
HP:0006510 Chronic pulmonary obstruction HPO 0.16
HP:0001635 Congestive heart failure HPO 0.15
HP:0006515 Interstitial pneumonitis HPO 0.13
HP:0002088 Abnormal lung morphology HPO 0.11

There are 5 clinical trials

Clinical Trials


1 CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR)

Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.

NCT02984761 Lung Neoplasm Radiation: Stereotactic Radiotherapy Procedure: Anatomic Pulmonary Resection
MeSH:Lung Neoplasms Neoplasms
HPO:Neoplasm Neoplasm of the lung

Primary Outcomes

Description: Survival estimates will include death from any cause.

Measure: Overall Survival

Time: From date of randomization through study completion, up to 10 years

Secondary Outcomes

Description: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and Lung Cancer (LC 13) survey instruments will assess patients' general state of physical, social/family, emotional and functional well-being.

Measure: Patient reported health-related quality of life

Time: 5 years

Description: The St George's Respiratory Questionnaire will evaluate respiratory symptoms, activity limitations from breathlessness, and impact of respiratory function on social and psychological functioning.

Measure: Respiratory Symptoms

Time: 5 years

Description: The EQ-5D-5L (EuroQOL-5D) survey will measure quality adjusted life years.

Measure: Health State Utilities

Time: 5 years

Description: Cause of death will be determined by an independent adjudication committee.

Measure: Lung cancer mortality

Time: From date of randomization until date of death from any cause, assessed up to 10 years.

Description: Post-treatment surveillance imaging will evaluate patients every 6 months for local, regional, and/or distant disease control.

Measure: Tumor patterns of failure

Time: 5 years

Description: The Forced Expiratory Volume at 1 second (FEV1) will evaluate an objective measure of breathing function.

Measure: Respiratory Function

Time: 5 years

2 Using the Electronic Health Record to Identify and Promote Goals-of-Care Communication for Older Patients With Serious Illness

The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.

NCT04281784 Dementia Chronic Disease Neoplasm Metastasis Lung Neoplasm Pulmonary Disease, Chronic Obstructive Heart Failure,Congestive Liver Cirrhosis Kidney Failure, Chronic Lung Diseases, Interstitial Peripheral Vascular Disease Diabetes With End Organ Injury Palliative Care, Patient Care Health Care Quality, Access, and Evaluation Patient Care Inpatients Health Communication Patient Care Planning Behavioral: EHR-based Clinician Jumpstart
MeSH:Neoplasm Metastasis Lung Neoplasms Liver Cirrhosis Lung Diseases Pulmonary Disease, Chronic Obstructive Lung Diseases, Interstitial Renal Insufficiency Kidney Failure, Chronic Heart Failure Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease Chronic Disease Neoplasms
HPO:Abnormal lung morphology Chronic pulmonary obstruction Cirrhosis Congestive heart failure Hepatic fibrosis Interstitial pneumonitis Interstitial pulmonary abnormality Left ventricular dysfunction Neoplasm Neoplasm of the lung Peripheral arterial stenosis Renal insufficiency Right ventricular failure

Primary Outcomes

Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.

Measure: EHR documentation of Goals of Care discussions

Time: Assessed for the period between randomization and 30 days following randomization

Secondary Outcomes

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU admissions

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU length of stay

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/Hospital use: Hospital length of stay

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: Hospital Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: ICU Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

Description: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.

Measure: Intensity of care: Healthcare costs

Time: 1 and 3 months after randomization

Description: From Washington State death certificates.

Measure: All-cause mortality at 1 year (safety outcome)

Time: 1 year after randomization

Other Outcomes

Description: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.

Measure: Key Implementation Factors

Time: 3 months after randomization

3 Observational Retrospective Register of Spanish Lung Cancer Patients With COVID19 Disease

This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.

NCT04344002 Covid-19 Lung Cancer
MeSH:Lung Neoplasms
HPO:Neoplasm of the lung

Primary Outcomes

Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.

Measure: Clinical data of lung cancer patients with COVID-19 diagnoses

Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis

Measure: Diagnosis data

Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received

Measure: Treatments received

Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.

Measure: Prognostic factors

Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

4 Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection

Observational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.

NCT04407143 Lung Cancer COVID Corona Virus Infection Diagnostic Test: IgG test
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Lung Neoplasms
HPO:Neoplasm of the lung

Primary Outcomes

Description: Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.

Measure: Description of the characteristics of patients

Time: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks

5 FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial

The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.

NCT04491084 Non Small Cell Lung Cancer Lung Cancer Drug: FLT3 Ligand Biological: anti-CD40 antibody Radiation: SBRT
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma

Primary Outcomes

Description: Death Any ≥ Grade 3 non-hematological toxicity, with the following exceptions: Grade 3 alopecia, vitiligo, or endocrinopathies controlled by hormone replacement therapy Grade 3 nausea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 vomiting and diarrhea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 fatigue that resolves to ≤ grade 2 within 5 days Grade 3 hypertension in the absence of maximal medical therapy Grade 3 adverse event of tumor flare (defined as local pain, irritation, or rash localized at sites of known or suspected tumor) of ≤ 7 days in duration Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations of pancreatitis. It is recommended to consult with the Principal Investigator for grade 4 amylase or lipase abnormalities Grade 3 clinically significant laboratory abnormalities that are asymptomatic and can be reversed within 72 hours, however: Any Grade 4

Measure: Phase I: Dose-limiting toxicity (DLT), defined as follows:

Time: up to 8 weeks after initiation of study therapy

Measure: Phase II: Progression-free survival (PFS) duration

Time: defined as time from study registration until disease progression (scored using iRECIST) or death, whichever comes first up to 51 weeks.

Secondary Outcomes

Description: Length of time that patient survives from time of study registration

Measure: Overall survival (OS) duration

Time: From date of registration until the date of death from any cause, assessed up to 2 years

Description: The clinical benefit rate (CBR) will be defined as the percentage of subjects who achieve best response of confirmed CR or PR, or stable disease (SD) for at least four months.

Measure: Radiographic responses using descriptive statistics

Time: From date of registration, assessed up to 4 months

Description: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. higher scores are a better level of functioning

Measure: Quality of Life using EORTC QLQ-LC13 (quality of Life Questionnaire, Lung Cancer)

Time: 1 year

Description: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. Most items are scored 1 to 4, higher scores are a better level of functioning.

Measure: Quality of Life using QLQ-C30 (Quality of Life Questionnaire)

Time: 1 year

Description: Average daily step counts

Measure: Daily step count using descriptive statistics

Time: 1 year


HPO Nodes